about
Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemiaWnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradationsBlocking TLR2 activity attenuates pulmonary metastases of tumor.Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm.The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia.Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.Antagonism of Interleukin-17A ameliorates experimental hepatic fibrosis by restoring the IL-10/STAT3-suppressed autophagy in hepatocytes.TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway.Glycogen synthase kinase-3beta negatively regulates TGF-beta1 and Angiotensin II-mediated cellular activity through interaction with Smad3.TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury.Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance.Cigarette smoke promotes COPD by activating platelet-activating factor receptor and inducing neutrophil autophagic death in mice.CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.Autophagy: a new pathway for traditional Chinese medicine.Toll like receptor 2 mediates bleomycin-induced acute lung injury, inflammation and fibrosis in mice.1,25-Dihydroxyvitamin D3 protects obese rats from metabolic syndrome via promoting regulatory T cell-mediated resolution of inflammation.TRIB3 Interacts with Beta-catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and TumorigenesisInhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibodyEndothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy[The advances of the drug therapy for pulmonary fibrosis]Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironmentMetformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expressionTumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR ActivationTargeting Extracellular Heat Shock Protein 70 Ameliorates Doxorubicin-Induced Heart Failure Through Resolution of Toll-Like Receptor 2-Mediated Myocardial InflammationImprovement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR graftingDisrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activationTRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcriptionTargeting Degradation of the Transcription Factor C/EBPβ Reduces Lung Fibrosis by Restoring Activity of the Ubiquitin-Editing Enzyme A20 in MacrophagesRegulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of th
P50
Q26795679-6BDE68DD-0118-4F0D-94C1-EB81A17B3C94Q28241703-3CC943D3-1007-4317-99AD-803A8AB90B82Q30008736-D055C76D-3FDB-4B1E-A384-EE2FF0D79638Q30663340-CAF7E965-D3C9-460D-93E5-235C9398DE65Q33490618-58A65664-D278-442D-B2D7-F710A03EC44DQ33774517-8D371C17-1B18-4E52-B8A5-E2CC6CE2CBE7Q34137016-C7331EA6-4B8B-4C92-992B-4C9111C85639Q34189274-7F8F33C6-1746-40C6-AB05-D885632CD7A1Q34448718-256D7EE9-7DE4-40BE-9921-3425E8B9B537Q36237998-A5B12774-411B-4EE7-8757-F16801AB5D53Q36433018-43C8481F-E83E-43C7-B03C-346EC6CD644CQ36515159-9C88FF7C-8B56-4411-9D1D-722B2D81D53EQ36595313-B4B7C53D-A2A8-47F8-B5AF-178C1968BF6EQ37320359-1F48DF4D-8897-4B2E-9D80-4BB717DFB35FQ37528063-8C654F5A-23F3-4183-91C5-29E7ADFBDC58Q37706081-CD4EF31A-81E3-487C-9465-713FD4DF5C62Q38704195-1D21026F-0837-4439-A847-87706571DD57Q39358801-DA3D7760-0E78-4E8D-AF21-AE4FC7A5AC7EQ39685049-F6C7ED5E-94A7-4E74-8934-329EBBF97C11Q42497019-83353BA4-20B3-4AA1-9885-E0D277DD47B6Q42805774-4A7529AD-E7FE-48AF-89CF-41008B945306Q44591933-343F3E41-E308-4CAC-A07C-3A995DAB2183Q46263005-62373439-5897-4BA0-88F2-22B54FB1164FQ47735324-ACEF4C12-144D-4A39-B549-B561C75F8097Q54610525-E0AFE6AD-024F-4FD1-A730-91BC008E3A25Q55361872-356EC0B8-F7E3-4275-A090-D3077394ADEBQ58574154-D963946F-B7B4-40D7-A5A0-2FA583E1D573Q61450449-0AB557EE-25B7-4DEA-8C63-4655694D2F39Q80673758-1C388369-DE09-4084-9217-E8A2F35B2502Q82085828-D19D2ABB-459D-4690-A4EA-9C7CE9E39A4CQ83089214-269460E0-991C-432B-9737-148CFDD93526Q88007972-05639CCD-D6E9-42CD-A0F0-F04E2AF5D41FQ88039890-B5710EAF-45CE-4692-826F-17AC6637F888Q90431745-64EAAD4C-F348-49BC-B47A-1899523CDB48Q90932118-D3131A2B-964C-4BCC-8B29-79A64FE4F260Q91733647-88CF6516-0FA0-4002-8129-6A4D6A63FCC3Q92024824-21080CD4-ACF5-40EF-906B-C9F446DC80F6Q93019946-D71C9CE0-3B7A-4B51-B448-27BC87CCFA13Q94205936-3012265C-4F82-457D-81F4-81FC40FC65BF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bing Cui
@ast
Bing Cui
@en
Bing Cui
@es
Bing Cui
@nl
Bing Cui
@sl
type
label
Bing Cui
@ast
Bing Cui
@en
Bing Cui
@es
Bing Cui
@nl
Bing Cui
@sl
prefLabel
Bing Cui
@ast
Bing Cui
@en
Bing Cui
@es
Bing Cui
@nl
Bing Cui
@sl
P106
P31
P496
0000-0001-8374-7801